Prevalence and Impact in Work Productivity of Gastroesophageal Reflux Disease (GERD) in Primary Care Patients With Upper Gastrointestinal (GI) Symptoms Using GerdQ
Completed
- Conditions
- Gastroesophageal Reflux Disease
- Registration Number
- NCT00914342
- Lead Sponsor
- AstraZeneca
- Brief Summary
The purpose of the study is to provide data on the GERD prevalence as percentage of patients with upper GI symptoms that are identified with GERD using the GerdQ Questionnaire. Furthermore the study aims to estimate GERD prevalence in patients based on their symptoms as they respond to a physician's questionnaire, to observe possible variations between the two methods (physicians' symptom rating and GerdQ), to objectively measure treatment response and to identify the percentage of patients that may require alterations of their treatment. Finally, to describe the impact of GERD symptoms on work productivity.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 889
Inclusion Criteria
- Patients with upper-GI symptoms the last week prior visiting the investigator
Exclusion Criteria
- History of oesophageal, gastric or duodenal surgery
- Treatment with NSAIDs/Acetylsalicylic acid within the last week prior to the study visit
- PPI use for healing of NSAIDs induced ulcer or for HP eradication
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method GERD prevalence as percentage of patients with upper GI symptoms that are identified with GERD using the GerdQ Questionnaire (GerdQ score >=8). Single Visit - once
- Secondary Outcome Measures
Name Time Method Describe the impact of GERD symptoms on work productivity. Single Visit - Once Estimation of GERD prevalence in patients based on their symptoms as they respond to a physician's questionnaire and to observe possible variations between the two methods (physicians' symptom rating and QerdQ) Single Visit - Once To objectively measure treatment response and to identify the percentage of patients that may require alterations of their treatment. Single Visit - Once
Trial Locations
- Locations (1)
Research Site
🇬🇷Xanthi, Greece